Nuvation Bio (Nuvation Bio) Accounts Payable : $2.21 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Accounts Payable?

Nuvation Bio's Accounts Payable for the quarter that ended in Dec. 2023 was $2.21 Mil.

Nuvation Bio's quarterly Accounts Payable declined from Jun. 2023 ($2.58 Mil) to Sep. 2023 ($2.37 Mil) and declined from Sep. 2023 ($2.37 Mil) to Dec. 2023 ($2.21 Mil).

Nuvation Bio's annual Accounts Payable declined from Dec. 2021 ($3.93 Mil) to Dec. 2022 ($2.14 Mil) but then increased from Dec. 2022 ($2.14 Mil) to Dec. 2023 ($2.21 Mil).

Nuvation Bio Accounts Payable Historical Data

The historical data trend for Nuvation Bio's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Accounts Payable Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Payable

2.17

3.93

2.14

2.21

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable	Get a 7-Day Free Trial											2.14	2.95	2.58	2.37	2.21

Nuvation Bio Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Nuvation Bio Accounts Payable Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).